No Data
Weigao Orthopedic: Shandong Weigao Orthopedic Materials Co., Ltd. Report for the third quarter of 2024
Shandong Weigao Orthopedic Materials Co., Ltd. Report for the third quarter of 2024
Weigao Orthopedics (688161.SH) declared a semi-annual dividend of 0.7 yuan per 10 shares with a record date of October 24th.
Weigao Orthopedics (688161.SH) announced that the company will implement the distribution of equity for the first half of 2024, with a distribution of 1...
Weigao Orthopedics (688161): The impact of orthopedic group procurement is gradually being resolved, and Q3 is expected to usher in a turning point in performance.
The core view of the company is that it is a leading player in the domestic orthopedic industry with a comprehensive product line. The performance in the first half of the year is in line with expectations. Since 2022, the company's various product lines have been successively affected by the price reduction of centralized procurement; currently, joint, trauma, and spine, the three major areas of centralized procurement have all been implemented.
Weigao Orthopedics (688161): Significant improvement in margin, bullish on continued improvement in the second half of the year.
Performance improves quarter by quarter, and the impact of centralized procurement is gradually clearing. In the first half of 2024, the company achieved revenue of 0.751 billion yuan (a decrease of 6.8% year-on-year), and net income attributable to shareholders of 0.093 billion yuan (a decrease of 16.7% year-on-year), which is the backbone product in the main business.
Shandong Weigao Orthopedic Materials Co., Ltd. 2024 Semi-Annual Report
No Data
No Data